Cited by 248Epigenetics and DNA MethylationSchizophrenia research and treatmentGenetic Associations and Epidemiology

Methylome-Wide Association Study of Schizophrenia: Identifying Blood Biomarker Signatures of Environmental Insults

Open access
Aberg, Karolina A., McClay, Joseph L., Nerella, Srilaxmi, Clark, Shaunna, Kumar, Gaurav, Chen, Wenan, Khachane, Amit N., Xie, Linying +7 more·2014·JAMA Psychiatry

Abstract

IMPORTANCE: Epigenetic studies present unique opportunities to advance schizophrenia research because they can potentially account for many of its clinical features and suggest novel strategies to improve disease management. OBJECTIVE: To identify schizophrenia DNA methylation biomarkers in blood. DESIGN, SETTING, AND PARTICIPANTS: The sample consisted of 759 schizophrenia cases and 738 controls (N = 1497) collected in Sweden. We used methyl-CpG-binding domain protein-enriched genome sequencing of the methylated genomic fraction, followed by next-generation DNA sequencing. We obtained a mean (SD) number of 68 (26.8) million reads per sample. This massive data set was processed using a specifically designed data analysis pipeline. Critical top findings from our methylome-wide association study (MWAS) were replicated in independent case-control participants using targeted pyrosequencing of bisulfite-converted DNA. MAIN OUTCOMES AND MEASURES: Status of schizophrenia cases and controls. RESULTS: Our MWAS suggested a considerable number of effects, with 25 sites passing the highly conservative Bonferroni correction and 139 sites significant at a false discovery rate of 0.01. Our top MWAS finding, which was located in FAM63B, replicated with P = 2.3 × 10-10. It was part of the networks regulated by microRNA that can be linked to neuronal differentiation and dopaminergic gene expression. Many other top MWAS results could be linked to hypoxia and, to a lesser extent, infection, suggesting that a record of pathogenic events may be preserved in the methylome. Our findings also implicated a site in RELN, one of the most frequently studied candidates in methylation studies of schizophrenia. CONCLUSIONS AND RELEVANCE: To our knowledge, the present study is one of the first MWASs of disease with a large sample size using a technology that provides good coverage of methylation sites across the genome. Our results demonstrated one of the unique features of methylation studies that can capture signatures of environmental insults in peripheral tissues. Our MWAS suggested testable hypotheses about disease mechanisms and yielded biomarkers that can potentially be used to improve disease management.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2013.3730

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Aberg, K. A., McClay, J. L., Nerella, S., Clark, S., Kumar, G., Chen, W., Khachane, A. N., Xie, L., Hudson, A., Gao, G., Harada, A., Hultman, C. M., Sullivan, P. F., Magnusson, P. K. E., & van den Oord, E. J. C. G.
Affiliations
  • Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, Richmond
  • Virginia Commonwealth University (US)
  • Karolinska Institutet (SE)
  • University of North Carolina at Chapel Hill (US)
Venue
JAMA Psychiatry
Published
2014-03-01
Volume
71
Issue
3
Pages
255
ISSN
2168-622X (ISSN-L)
OpenAlex
W2094005621
Cited by
248
References
78
Citations by year
2026: 4 · 2025: 6 · 2024: 7 · 2023: 11 · 2022: 11 · 2021: 14 · 2020: 17 · 2019: 15 · 2018: 39 · 2017: 27 · 2016: 40 · 2015: 32 · 2014: 25
FWCI
16.85
Type
journal article
Language
en
Open access
Locations
  • JAMA Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Alcohol Abuse and Alcoholism (K01AA021266)
  • National Institute of Mental Health (R01MH077139, MH077139, RC2MH089996)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
schizophrenia, DNA methylation, methylome-wide association study, reelin, hypoxia, infection, neuronal differentiation, epigenetics
MeSH terms
Reelin Protein, Humans, Registries, Schizophrenia, Sweden, Biomarkers, Sequence Analysis, DNA, DNA Methylation, Genome-Wide Association Study, Epigenomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review